Belzutifan vs Everolimus for advanced RCC second line post IO plus TKI. Inspite of exactly same median pfs ( 5.6 months in both arms ) and curves crossing each other) at second interim analysis at 18 months, PFS curves are well separated ( unequal censoring ??) and p value

Does covid-19 still has same impact in your country as it was during 2020-21 ? Do u think covid-19 is something to worry of beyond usual viral fever with cough and cold ? Does this vaccine still needs emergency use authorisation? My answer - NO for all 3 Vinay Prasad MD MPH

Lung cancer vaccine phase 2 trial has started in various countries and it is making news headlines . This is Lu-Ca-Merit -1 trial and name of vaccine is BNT-116 - It is IV mRNA Vaccine and it will be studied in combination with cemiplimab and Chemotherapy in various cohorts

Tissue agnostic approvals from 2017 till now ESMO - Eur. Oncology . Lets see the Other side of the coin. 1 - It is great to have Tissue Agnostic approvals and works well for NTRK fusion, B-RAF mutation and RET fusion and to some extent for MSI high . But for HER2-3 plus and TMB high

Esmo presidential sessions ESMO - Eur. Oncology #ESMO24 What is the exciting data to look forward to - My Take 1 - OS data for Keynote- 522 - pembrolizumab for Neoadjuvant TNBC. 2- NIAGARA - neoadjuvant Durvalumab plus chemo followed by sx and adjuvant Durvalumab for MIBC . 3 - OS data

oncologynewscentral.com/article/fda-op… Hello everyone, Do read my Opinon piece published on oncology news central Oncology News Central, about recent USFDA approval of blood based colon cancer screening test . Do give your feedback and opinions 🙂 LARVOL Cancer Data etc OncoAlert FDA Oncology

New blood test for #colorectal cancer approved by FDA raises concerns with only 13.2% sensitivity for precancerous lesions. What does this mean for oncologists about the certainty of a negative test? bit.ly/4g0W2lY #CRC Dr Amol Akhade NEJM

Dr Amol Akhade Oncology News Central LARVOL Cancer Data etc OncoAlert FDA Oncology We would like to inform you that your post has been successfully published on @Oncodaily. Thank you for sharing! oncodaily.com/blog/132619

Whats new data coming up at ESMO - Eur. Oncology #esmo24 in lung cancer ? What's coming up for Lung Cancer In ESMO 24 ? My Take Phase 3 data - 1- adjuvant durvalumab alone in completely resected NSCLC 2- second interim OS from Mariposa-2 trial 3 - low dose vs standard dose

Dr.Dr Amol Akhade about FDA Oncology approval of blood based colon cancer screening test Oncology News Central oncodaily.com/blog/132619 #Cancer #BloodCancer #OncEd #CancerScreening #OncoDaily #Oncology

What's the new ADC data coming up from ESMO 24 ? Puxitatug samrotecan ( anti -B7-H4 ADC ) probably looks most promising . Rinatabart Sesutecan already has FDA fast track Designation ( FR-alpha ADC ) New Cludin6 and Claudin 18.2 ADC, Anti Her2 ADC and Trop 2 ADC data needs to

May Lord Ganesha Bless you all . Dagdu Sheth Halwai Ganpati at Pune , India 🇮🇳 🙏🙏

What's new data coming up in PD-L1 negative advanced NSCLC? Volrustomig , monoclonal bispecific antibody in combination with chemotherapy for First line mNSCLC shows good ORR and DCR in phase 1b trial in both non Squamous and Squamous histology. But 7 treatment related deaths ,

Doxorubicin plus Trabectedin followed by Trabectedin maintenance for leiomyosarcoma shows OS benifit vs doxorubicin alone . Median OS Improved from 24 months to 33 months NEJM See the post progression therapy for both arms ( 36 % of control arm got Trabectedin on

Ivonescimab vs Pembrolizumab. For First line NSCLC. Harmoni-2 trial. Remember PFS is already declared postive as clinically meaningful. In both Squamous and Non Squamous histology and in both PDL1 low and high subsets . Full data on this Sunday at #WCLC24 This is going to be

In Clinical Oncology, Dr Mark Lythgoe and I comment on the state of supportive care in oncology. Metrics including drug approvals, global funding, and the number of ongoing clinical trials show a predominant focus on anti-cancer therapeutics over supportive care interventions.

Dr Amol Akhade Interesting blog on the HARMONI-2 backstory 👉The Wild West of World Lung Cancer #WCLC24 kolpulse.com/uptempo-blog/t…